OTC:SYRA
Syra Health Corp
A niche healthcare services firm facilitating clinical trials with a focus on patient recruitment and site management.
Key Metrics
Investment Thesis
Bull Case
If Syra can successfully convert its growing revenue base into profitability by controlling operating costs, it could unlock significant value for early investors. The rapid 45% year-over-year revenue growth demonstrates strong market demand for their niche clinical trial services and efficient patient recruitment capabilities. Success in turning the current cash burn positive would transform SYRA from a speculative biotech play into a stable healthcare services asset.
Bear Case
The company is losing money at an accelerating rate, burning cash faster than it can raise through equity issuances or operations. With a retained earnings deficit of $8.8M and limited current assets relative to liabilities, the balance sheet is fragile and vulnerable to any market downturn. Continued reliance on dilutive capital raises suggests management cannot achieve sustainable growth without a major pivot or acquisition partner.
About Syra Health Corp
Syra Health Corp (SYRA) is a healthcare services provider focusing on clinical trials and patient recruitment across North America. The company leverages its specialized network to connect pharmaceutical sponsors with trial sites, generating revenue from service fees and performance-based incentives. With operations primarily in the United States, Syra aims to streamline the drug development process by accelerating study enrollment.
Analysis
Management Discussion
Despite a 45% revenue increase from $5.5M in 2023 to $8.0M in 2024, profitability deteriorated with net income falling to -$3.8M from -$2.9M last year. Operating expenses surged to $5.4M, outpacing the growth in gross profit which remained relatively flat at $1.7M, highlighting inefficient scaling. The company burned through approximately $3.0M of cash while relying on equity raises rather than organic funding to cover the gap.
Industry Overview
The clinical trials industry is experiencing steady expansion driven by an aging population and increased investment in biopharmaceutical research and development. Companies specializing in patient recruitment and site management are gaining importance as sponsors seek to reduce trial timelines and costs. However, the sector faces intense competition from larger CROs and requires high levels of compliance expertise to operate successfully.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 |
|---|---|---|
| Revenue | $5.5M | $8.0M |
| Cost of Revenue | $4.1M | $6.3M |
| Gross Profit | $1.4M | $1.7M |
| Operating Expenses | $4.3M | $5.4M |
| Operating Income | $-2.9M | $-3.8M |
| R&D | $240.0K | $585.1K |
| G&A | $1.1M | $1.4M |
| Stock-Based Comp | $32.8K | $59.8K |
| Depreciation | $48.8K | $62.7K |
| Other OpEx | $2.9M | $3.4M |
| Non-Operating Income | $0 | $0 |
| Interest Expense | $53.7K | $15.6K |
| Interest Income | $2.9K | $21.2K |
| Pre-Tax Income | $-2.9M | $-3.8M |
| Income Tax | $50.7K | $-5.6K |
| Continuing Ops | $-2.9M | $-3.8M |
| Discontinued Ops | $0 | $0 |
| Net Income | $-2.9M | $-3.8M |
| Minority Interest | $0 | $0 |
| Net to Common | $-2.9M | $-3.8M |
| Metric | 2023 | 2024 |
|---|---|---|
| Current Assets | $4.8M | $3.4M |
| Cash & Equivalents | $3.3M | $2.4M |
| Prepaid Expenses | — | $276.6K |
| Other Current Assets | $1.5M | $680.8K |
| Long-Term Assets | $142.2K | $326.5K |
| PP&E (Net) | $79.0K | $27.3K |
| Operating Leases | $63.2K | $299.2K |
| Other LT Assets | $0 | $0 |
| Total Assets | $4.9M | $3.7M |
| Current Liabilities | $910.1K | $613.5K |
| Accounts Payable | — | $101.7K |
| Current Leases | $63.2K | $112.0K |
| Other Current Liab | $647.9K | $169.5K |
| Long-Term Liabilities | $0 | $187.2K |
| LT Operating Leases | — | $187.2K |
| Other LT Liab | — | $0 |
| Total Liabilities | $910.1K | $800.8K |
| Shareholders' Equity | $4.0M | $2.9M |
| Paid-In Capital | $9.1M | $11.7M |
| Retained Earnings | $-5.1M | $-8.8M |
| Total L&E | $4.9M | $3.7M |
| Metric | 2023 | 2024 |
|---|---|---|
| Net Income (CFO) | $-2.9M | $-3.8M |
| Non-Cash Adjustments | $509.7K | $2.1M |
| Working Capital Changes | $-330.4K | $-1.3M |
| Cash from Operations | $-2.8M | $-2.9M |
| Capital Expenditures | $15.3K | $11.1K |
| Cash from Investing | $-15.3K | $-11.1K |
| Cash from Financing | $6.1M | $2.1M |
| FX Effect | $0 | $0 |
| Net Change in Cash | $3.3M | $-884.7K |
| Beginning Cash | $3.3K | $3.3M |
| Ending Cash | $3.3M | $2.4M |
Frequently Asked Questions
How does Syra Health Corp make money?
Primary revenue streams include direct clinical trial services such as patient identification and screening, site management and coordination fees, and performance-based incentives tied to successful trial outcomes. Secondary segments involve consulting services for sponsors and data management support to optimize study efficiency across therapeutic areas.
What are the main risks for SYRA?
Persistent operating losses of $3.8M in 2024 indicate significant burn rates that threaten financial stability given limited cash reserves of $2.4M. The company relies heavily on common share issuances ($2.5M) to fund operations, which dilutes existing shareholders and may not be sustainable long-term. Revenue concentration in a volatile clinical trial market exposes the business to sponsor funding delays or project cancellations. High accounts payable ($101k) and accrued expenses ($230k) suggest potential liquidity pressures if cash inflows do not improve immediately.
What is SYRA's competitive advantage?
The company possesses a proprietary network of specialized clinical sites that can rapidly identify and enroll patients for niche therapeutic trials. Its agile operational model allows it to scale recruitment efforts quickly in response to sponsor demand without heavy capital expenditure. Syra's deep expertise in navigating regulatory compliance reduces the administrative burden for pharmaceutical sponsors, creating a sticky client relationship.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.